Exhibit 4.9


 





UNLESS PERMITTED UNDER SECURITIES
LEGISLATION, THE HOLDER OF THIS SECURITY AND ANY SECURITY ISSUED ON EXERCISE HEREOF MUST NOT TRADE THE SECURITY


BEFORE JANUARY 21, 2014.


 


WITHOUT PRIOR APPROVAL OF
THE TSX VENTURE EXCHANGE (THE “EXCHANGE”) AND COMPLIANCE WITH ALL APPLICABLE SECURITIES LEGISLATION, THE SECURITIES
REPRESENTED BY THIS CERTIFICATE AND ANY SECURITIES ISSUED ON EXERCISE HEREOF MAY NOT BE SOLD, TRANSFERRED, HYPOTHECATED OR OTHERWISE
TRADED ON OR THROUGH THE FACILITIES OF THE EXCHANGE OR OTHERWISE IN CANADA OR TO OR FOR THE BENEFIT OF A CANADIAN RESIDENT UNTIL
JANUARY 21, 2014.


 


THIS WARRANT AND THE SECURITIES
DELIVERABLE UPON EXERCISE THEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “1933
ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES, AND MAY NOT BE SOLD, PLEDGED, HYPOTHECATED, DONATED OR OTHERWISE
TRANSFERRED WITHOUT COMPLIANCE WITH THE REGISTRATION OR QUALIFICATION PROVISIONS OF APPLICABLE UNITED STATES FEDERAL AND STATE
SECURITIES LAWS OR WITHOUT DELIVERING AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.
DELIVERY OF THIS WARRANT MAY NOT CONSTITUTE “GOOD DELIVERY” IN SETTLEMENT OF TRANSACTIONS ON STOCK EXCHANGES IN CANADA.


 


THIS WARRANT CERTIFICATE
IS VOID IF NOT EXERCISED ON OR BEFORE 5:00 P.M. (PACIFIC TIME) ON SEPTEMBER 20, 2016.


 


WARRANT CERTIFICATE


 


STELLAR BIOTECHNOLOGIES,
INC.


(Continued under the laws of
the Province of British Columbia)


 


	WARRANT



CERTIFICATE NO.  2013-	                                       WARRANTS
    entitling the holder  to acquire, subject to adjustment, one Common Share for each Warrant represented
    hereby.


 


THIS IS
TO CERTIFY THAT [Name] of [Address] (hereinafter referred to as the “holder” or the “Warrantholder”)
is entitled to acquire for each Warrant represented hereby, in the manner and subject to the restrictions and adjustments set forth
herein, at any time and from time to time until 5:00 p.m. (Pacific time) (the “Expiry Time”) on September 20,
2016 (the “Expiry Date”), one fully paid and non-assessable common share (“Common Share”)
in the capital of STELLAR BIOTECHNOLOGIES, INC., a corporation formed under the laws of the province of British Columbia, Canada
(the “Company”).


 


These Warrants
may only be exercised at the head office of the Company located at 332 East Scott Street, Port Hueneme, California, 93041, or the
registered office of the Company located at Suite 401, 1231 Barclay Street, Vancouver, British Columbia, V6E 1H5 (or such other
office or agency of the Company as it may designate by notice in writing to the Warrantholder at the address of the Warrantholder
appearing on the books of the Company).


 


These Warrants are issued subject to the terms and
conditions appended hereto as Schedule “A”.


 


IN WITNESS
WHEREOF, the Company has caused this Warrant Certificate to be executed by a duly authorized officer of the Company.


 


DATED for reference the 20th day
of September, 2013.


 




     


     

    

 


	 	STELLAR BIOTECHNOLOGIES, INC.
	 	 
	 	Per:	 
	 	 	Scott Davis, Chief Financial Officer


 


(See terms and conditions attached hereto)


 




     


     

    

 


SCHEDULE “A”


 


TERMS AND CONDITIONS FOR WARRANT CERTIFICATE


 


Terms and
Conditions attached to the Warrant Certificate issued by STELLAR BIOTECHNOLOGIES, INC. (the “Company”)
and dated for reference the 20th day of September, 2013.


 


ARTICLE 1


INTERPRETATION


 


1.1           Definitions.
In these Terms and Conditions, unless there is something in the subject matter or context inconsistent therewith:


 


(a)          “1933
Act” means the United States Securities Act of 1933, as amended;


 


(b)          “Common
Shares” means the common shares in the capital of the Company to be issued pursuant to the exercise of Warrants;


 


(c)          “Company”
means STELLAR BIOTECHNOLOGIES, INC., a corporation formed under the laws of the province of British Columbia, Canada unless
and until a successor corporation shall have become such in the manner prescribed in Article 6, and thereafter “Company”
shall mean such successor corporation;


 


(d)          “Company’s
Auditors” means an independent firm of accountants duly appointed as auditors of the Company;


 


(e)          “Dollars”
or use of signs “US $” or “$” means only lawful money of the United States and not any other
currency, regardless of whether that currency uses the “$” sign to denote its currency or may be readily converted
into lawful money of the United States;


 


(f)          “Exchange”
means the TSX Venture Exchange or such other stock exchange on which the Company’s Common Shares are listed and posted for
trading; Schedule “A”;


 


(g)          “Exercise
Date” has that meaning ascribed to that term in Section 3.2 of this before September 20, 2016;


 


(h)          “Exercise
Price” means the price of US $1.35 per share if exercised on or


 


(i)          “Expiry
Time” means 5:00 p.m. (Pacific Time) on the Expiry Date;


 


(j)          “Expiry
Date” means September 20, 2016.


 


(k)          “herein”,
“hereby” and similar expressions refer to these Terms and Conditions as the same may be amended or modified
from time to time; and the expression “Article” and “Section” followed by a number refer to the specified
Article or Section of these Terms and Conditions;


 




    	 	A-1	 



     


    

 


(l)          “Issue
Date” means the issue date of the Warrant shown on the face page of the Warrant Certificate;


 


(m)          “person”
means an individual, corporation, partnership, trustee or any unincorporated organization and words importing persons have a similar
meaning;


 


(n)          “Subscription
Form” has that meaning ascribed to that term in Section 3.1 of this Schedule “A”;


 


(o)          “United
States” has that meaning ascribed to it in Rule 902(1) of Regulation S;


 


(p)          “Warrant”
means the warrant to acquire Common Shares evidenced by the Warrant Certificate; and


 


(q)          “Warrant
Certificate” means the certificate to which these Terms and Conditions are attached.


 


1.2           Interpretation
Not Affected by Headings.


 


(a)          The
division of these Terms and Conditions into Articles and Sections, and the insertion of headings are for convenience of reference
only and shall not affect the construction or interpretation thereof.


 


(b)          Words
importing the singular number include the plural and vice versa and words importing the masculine gender include the feminine and
neuter genders.


 


1.3           Applicable
Law. The terms hereof and of the Warrant shall be construed in accordance with the laws of the Province of British Columbia
and the laws of Canada, and the parties hereto irrevocably attorn and submit to the exclusive jurisdiction of the courts of British
Columbia with respect to any dispute related to this Warrant.


 


ARTICLE 2


ISSUE OF WARRANT


 


2.1           Issue
of Warrants. That number of Warrants set out on the Warrant Certificate are hereby created and authorized to be issued.


 


2.2           Additional
Warrants. Subject to any other written agreement between the Company and the Warrantholder, the Company may at any time and
from time to time undertake further equity or debt financing and may issue additional Common Shares, warrants or grant options
or similar rights to purchase Common Shares to any person.


 


2.3           Issue
in Substitution for Lost Warrants. If the Warrant Certificate becomes mutilated, lost, destroyed or stolen:


 


 (a)          the
Company shall issue and deliver a new Warrant Certificate of like date and tenor as the one mutilated, lost, destroyed or stolen,
in exchange for and in place of and upon cancellation of such mutilated, lost, destroyed or stolen Warrant Certificate; and


 




    	 	A-2	 



     


    

 


 (b)          the
holder shall bear the cost of the issue of a new Warrant Certificate hereunder and in the case of the loss, destruction or theft
of the Warrant Certificate, shall furnish to the Company such evidence of loss, destruction, or theft as shall be satisfactory
to the Company in its discretion and the Company may also require the holder to furnish indemnity in an amount and form satisfactory
to the Company in its discretion, and shall pay the reasonable charges of the Company in connection therewith.


 


2.4           Warrantholder
Not a Shareholder. The Warrant shall not constitute the holder a shareholder of the Company, nor entitle it to any right or
interest in respect thereof (including but not limited to voting rights) except as may be expressly provided in the Warrant.


 


ARTICLE 3


EXERCISE OF THE WARRANT


 


3.1           Method
of Exercise of the Warrant. The right to purchase Common Shares conferred by the Warrant Certificate may be exercised, prior
to the Expiry Time, by the holder delivering to the Company (whether via facsimile or otherwise) a duly completed and executed
subscription form substantially in the form attached hereto as Schedule “B” (the “Subscription Form”)
and a certified check, bank draft, wire transfer or a money order payable to or to the order of the Company, for the Exercise Price
applicable at the time of exercise in respect of the Common Shares subscribed for in lawful money of the United States, to the
Company.


 


3.2           Effective
Date of Exercise of the Warrant. This Warrant Certificate together with such Subscription Form, certified check, bank draft,
wire transfer or a money order will be deemed to be exercised only upon actual receipt thereof by the Company as set out above
(the “Exercise Date”).


 


3.3           Effect
of Exercise of the Warrant.


 


(a)          Upon
delivery of the Subscription Form and payment as aforesaid the Common Shares so subscribed for shall be issued as fully paid and
non-assessable shares and the holder shall become the holder of record of such Common Shares on the date of such delivery and such
payment; and


 


(b)          Within
five business days after delivery and payment as aforesaid, the Company shall forthwith cause the issuance to the holder of a certificate
for the Common Shares purchased as aforesaid.


 


3.4           Subscription
for Less than Entitlement. The holder may subscribe for and purchase a number of Common Shares less than the number which it
is entitled to purchase pursuant to this Warrant Certificate. Execution and delivery of a Subscription Form with respect to less
than all of the shares underlying this Warrant shall have the same effect as cancellation of the original of this Warrant and issuance
of a new Warrant evidencing the right to purchase the remaining number of shares underlying this Warrant. Execution and delivery
of a Subscription Form for all of the then- remaining shares underlying this Warrant shall have the same effect as cancellation
of the original of this Warrant after delivery of the shares underlying this Warrant in accordance with the terms hereof.


 


3.5           Expiration
of the Warrant. After the Expiry Time all rights hereunder shall wholly cease and terminate and the Warrant shall be void and
of no effect.


 




    	 	A-3	 



     


    

 


3.6           Hold
Periods and Legending of Share Certificate. The certificates representing the Common Shares to be issued pursuant to the exercise
of this Warrant shall bear a legend in substantially the following forms:


 


 (a)


 


“THE
SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”),
AND MAY NOT BE SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER
THE 1933 ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE ISSUER OF THIS CERTIFICATE THAT REGISTRATION IS NOT REQUIRED UNDER THE
1933 ACT.”


 


 (b)


 


“Unless permitted under
securities legislation, the holder of the securities shall not trade the securities before January 21, 2014.”


 


“Without prior written approval
of the TSX Venture Exchange and compliance with all applicable securities legislation, the securities represented by this certificate
may not be sold, transferred, hypothecated or otherwise traded on or through the facilities of the TSX Venture Exchange or otherwise
in Canada or to or for the benefit of a Canadian resident until January 21, 2014.”


 


ARTICLE 4


ADJUSTMENTS


 


4.1           Adjustments.
The number of Common Shares purchasable upon the exercise of each Warrant and the Exercise Price shall be subject to adjustment
as follows:


 


 (a)          in
the event the Company shall:


 


(i)          pay
a dividend in Common Shares or make a distribution in Common Shares;


 


(ii)         subdivide
its outstanding Common Shares;


 


(iii)        combine
its outstanding Common Shares into a smaller number of Common Shares; or


 


(iv)        issue
by reclassification of its Common Shares other securities of the Company (including any such reclassification in connection with
a consolidation, merger, amalgamation or other combination in which the Company is the surviving corporation);


 




    	 	A-4	 



     


    

 


the number of Common Shares (or
other securities) purchasable upon exercise of each Warrant immediately prior thereto shall be adjusted so that the Warrantholder
shall be entitled to receive the kind and number of Common Shares or other securities of the Company which it would have owned
or have been entitled to receive after the happening of any of the events described above, had such Warrant been exercised immediately
prior to the happening of such event or any record date with respect thereto. An adjustment made pursuant to this subsection (a)
shall become effective immediately after the effective date of such event retroactive to the record date, if any, for such event.


 


 (b)          In
case the Company shall issue rights, options or warrants to all or substantially all holders of its outstanding Common Shares,
without any charge to such holders, entitling them (for a period within 45 days after the record date mentioned below) to subscribe
for or purchase Common Shares at a price per share which is lower than 95% of the current market price at the record date mentioned
below (as determined in accordance with subsection (d) below), the number of Common Shares thereafter purchasable upon the exercise
of each Warrant shall be determined by multiplying the number of Common Shares theretofore purchasable upon exercise of each Warrant
by a fraction, of which the numerator shall be the number of Common Shares outstanding on the date of issuance of such rights,
options or warrants plus the number of additional Common Shares offered for subscription or purchase, and of which the denominator
shall be the number of Common Shares outstanding on the date of issuance of such rights, options or warrants plus the number of
shares which the aggregate offering price of the total number of Common Shares so offered would purchase at the current market
price per Common Share at such record date. Such adjustment shall be made whenever such rights, options or warrants are issued,
and shall become effective immediately after the record date for the determination of shareholders entitled to receive such rights,
options or warrants.


 


 (c)          In
case the Company shall distribute to all or substantially all holders of its Common Shares evidences of its indebtedness or assets
(excluding cash dividends or distributions payable out of consolidated earnings or earned surplus and dividends or distributions
referred to in subsection (a) above or in subsection (d) below or rights, options or warrants, or convertible or exchangeable securities
containing the right to subscribe for or purchase Common Shares (excluding those referred to in subsection (b) above)), then in
each case the number of Common Shares thereafter purchasable upon the exercise of each Warrant shall be determined by multiplying
the number of Common Shares theretofore purchasable upon the exercise of each Warrant by a fraction, of which the numerator shall
be the then current market price per Common Share (as determined in accordance with subsection (d) below) on the date of such distribution,
and of which the denominator shall be the then current market price per Common Share less the then fair value (as determined by
the board of directors of the Company, acting reasonably) of the portion of the assets or evidences of indebtedness so distributed
or of such subscription rights, options or warrants, or of such convertible or exchangeable securities applicable to one Common
Share. Such adjustment shall be made whenever any such distribution is made, and shall become effective on the date of distribution
retroactive to the record date for the determination of shareholders entitled to receive such distribution.


 


In the event
of the distribution by the Company to all or substantially all of the holders of its Common Shares of shares of a subsidiary or
securities convertible or exercisable for such shares, then in lieu of an adjustment in the number of Common Shares purchasable
upon the exercise of each Warrant, the Warrantholder of each Warrant, upon the exercise thereof, shall receive from the Company,
such subsidiary or both, as the Company shall reasonably determine, the shares or other securities to which such Warrantholder
would have been entitled if such Warrantholder had exercised such Warrant immediately prior thereto, all subject to further adjustment
as provided in this Section 4.1 provided, however, that no adjustment in respect of dividends or interest on such shares or other
securities shall be made during the term of a Warrant or upon the exercise of a Warrant.


 




    	 	A-5	 



     


    

 


 (d)          For
the purpose of any computation under subsections (b) and (c) of this Section 4.1, the current market price per Common Share at
any date shall be the weighted average price per Common Share for twenty-five (25) consecutive trading days, commencing not more
than 45 trading days before such date on the stock exchange on which the Common Shares are then traded; provided if the Common
Shares are then traded on more than one stock exchange, then on the stock exchange on which the largest volume of Common Shares
were traded during such twenty-five (25) consecutive trading day period. The weighted average price per Common Share shall
be determined by dividing the aggregate sale price of all Common Shares sold on such exchange or market, as the case may be, during
the said twenty-five (25) consecutive trading days by the total number of shares so sold. For purposes of this subsection (d),
trading day means, with respect to a stock exchange, a day on which such exchange is open for the transaction of business. Should
the Common Shares not be listed on any stock exchange the current market price per Common Share at any date shall be determined
by the board of directors of the Company, acting reasonably.


 


 (e)          In
any case in which this Article 4 shall require that any adjustment in the Exercise Price be made effective immediately after a
record date for a specified event, the Company may elect to defer until the occurrence of the event the issuance, to the holder
of any Warrant exercised after that record date, of the Common Shares and other shares of the Company, if any, issuable upon the
exercise of the Warrant over and above the Common Shares and other shares of the Company; provided, however, that the Company shall
deliver to the holder an appropriate instrument evidencing the holder’s right to receive such additional shares upon the
occurrence of the event requiring such adjustment.


 


 (f)          No
adjustment in the number of Common Shares purchasable hereunder shall be required unless such adjustment would require an increase
or decrease of at least one percent (1%) in the number of Common Shares purchasable upon the exercise of each Warrant; provided,
however, that any adjustments which by reason of this subsection (f) are not required to be made shall be carried forward and taken
into account in any subsequent adjustment. All calculations shall be made to the nearest one-hundredth of a share.


 


 (g)          Wherever
the number of Common Shares purchasable upon the exercise of each Warrant is adjusted, as herein provided, the Exercise Price payable
upon exercise of each Warrant shall be adjusted by multiplying such Exercise Price immediately prior to such adjustment by a fraction,
of which the numerator shall be the number of Common Shares purchasable upon the exercise of such Warrant immediately prior to
such adjustment, and of which the denominator shall be the number of Common Shares purchasable immediately thereafter.


 


 (h)          No
adjustment in the number of Common Shares purchasable upon the exercise of each Warrant need be made under subsections (b) and
(c) if, the Company issues or distributes to the Warrantholder the rights, options, warrants, or convertible or exchangeable securities,
or evidences of indebtedness or assets referred to in those subsections which the Warrantholder would have been entitled to receive
had the Warrants been exercised prior to the happening of such event or the record date with respect thereto.


 




    	 	A-6	 



     


    

 


 (i)          In
the event that at any time, as a result of an adjustment made pursuant to subsection (a) above, the Warrantholder shall
become entitled to purchase any securities of the Company other than Common Shares, thereafter the number of such
other shares so purchasable upon exercise of each Warrant and the Exercise Price of such shares shall be subject to
adjustment from time to time in a manner and on terms as nearly equivalent as practicable to the provisions with respect to
the Common Shares contained in subsections (a) through (h), inclusive, above, and the provisions of sections 4.2 through 4.4,
inclusive, of this Article 4 with respect to the Common Shares, shall apply on like terms to any such other securities.


 


 (j)          Upon
the expiration of any rights, options, warrants or conversion or exchange privileges, if any thereof shall not have been exercised,
the Exercise Price and the number of Common Shares purchasable upon the exercise of each Warrant shall, upon such expiration, be
readjusted and shall thereafter be such as it would have been had it been originally adjusted (or had the original adjustment not
been required, as the case may be) as if:


 


(i)          the
only Common Shares so issued were the Common Shares, if any, actually issued or sold upon the exercise of such rights, options,
warrants or conversion or exchange rights; and


 


(ii)         such
Common Shares, if any, were issued or sold for the consideration actually received by the Company upon such exercise plus the aggregate
consideration, if any, actually received by the Company for the issuance, sale or grant of all such rights, options, warrants or
conversion or exchange rights whether or not exercised;


 


provided further, that no such
readjustment shall have the effect of increasing the Exercise Price or decreasing the number of Common Shares purchasable upon
the exercise of each Warrant by an amount in excess of the amount of the adjustment initially made with respect to the issuance,
sale or grant of such rights, options, warrants or conversion or exchange rights.


 


4.2           Voluntary
Adjustment by the Company. Subject to requisite Exchange approval, the Company may, at its option, at any time during the term
of the Warrants, reduce the then current Exercise Price to any amount deemed appropriate by the Board of Directors of the Company.


 


4.3           Notice
of Adjustment. Whenever the number of Common Shares purchasable upon the exercise of each Warrant or the Exercise Price of
such Common Shares is adjusted, as herein provided, the Company shall promptly send to the Warrantholder by first class mail, postage
prepaid, notice of such adjustment or adjustments.


 


4.4           No
Adjustment for Dividends. Except as provided in Section 4.1 of this Article 4, no adjustment in respect of any dividends shall
be made during the term of a Warrant or upon the exercise of a Warrant.


 


4.5           Preservation
of Purchase Rights Upon Merger, Consolidation, etc. In connection with any consolidation of the Company with, or amalgamation
or merger of the Company with or into, another corporation (including, without limitation, pursuant to a “takeover bid”,
“tender offer” or other acquisition of all or substantially all of the outstanding Common Shares) or in case of any
sale, transfer or lease to another corporation of all or substantially all the property of the Company, the Company or such successor
or purchasing corporation, as the case may be, shall execute with the Warrantholder an agreement that the Warrantholder shall have
the right thereafter, upon payment of the Exercise Price in effect immediately prior to such action, to purchase upon exercise
of each Warrant the kind and amount of shares and other securities and property which it would have owned or have been entitled
to receive after the happening of such consolidation, amalgamation, merger, sale, transfer or lease had such Warrant been exercised
immediately prior to such action, and the Warrantholder shall be bound to accept such shares and other securities and property
in lieu of the Common Shares to which it was previously entitled; provided, however, that no adjustment in respect of dividends,
interest or other income on or from such shares or other securities and property shall be made during the term of a Warrant or
upon the exercise of a Warrant. Any such agreement shall provide for adjustments, which shall be as nearly equivalent as may be
practicable to the adjustments provided for in this Schedule “A”. The provisions of this Article 4 shall similarly
apply to successive consolidations, mergers, amalgamation, sales, transfers or leases.


 




    	 	A-7	 



     


    

 


4.6           Determination
of Adjustments. If any questions shall at any time arise with respect to the Exercise Price, such question shall be conclusively
determined by the Company’s Auditors, or, if they decline to so act, any other firm of Chartered Accountants, in Vancouver,
British Columbia, that the Company may designate and the Warrantholder, acting reasonably, may approve, and who shall have access
to all appropriate records and such determination shall be binding upon the Company and the holder.


 


ARTICLE 5

COVENANTS BY THE COMPANY


 


5.1           Reservation
of Common Shares. The Company will reserve and there will remain unissued out of its authorized capital a sufficient number
of Common Shares to satisfy the rights of acquisition provided for in the Warrant Certificate.


 


ARTICLE 6


MERGER AND SUCCESSORS


 


6.1           Company
May Consolidate, etc. on Certain Terms. Nothing herein contained shall prevent any consolidation, amalgamation or merger of
the Company with or into any other corporation or corporations, or a conveyance or transfer of all or substantially all the properties
and estates of the Company as an entirety to any corporation lawfully entitled to acquire and operate same, provided, however,
that the corporation formed by such consolidation, amalgamation or merger or which acquires by conveyance or transfer all or substantially
all the properties and estates of the Company as an entirety shall, simultaneously with such amalgamation, merger, conveyance or
transfer, assume the due and punctual performance and observance of all the covenants and conditions hereof to be performed or
observed by the Company.


 


6.2           Successor
Company Substituted. In case the Company, pursuant to Section 6.1 shall be consolidated, amalgamated or merged with or into
any other corporation or corporations or shall convey or transfer all or substantially all of its properties and estates as an
entirety to any other corporation, the successor corporation formed by such consolidation or amalgamation, or into which the Company
shall have been consolidated, amalgamated or merged or which shall have received a conveyance or transfer as aforesaid, shall succeed
to and be substituted for the Company hereunder and such changes in phraseology and form (but not in substance) may be made in
the Warrant Certificate and herein as may be appropriate in view of such amalgamation, merger or transfer.


 




    	 	A-8	 



     


    

 


ARTICLE 7


AMENDMENTS


 


7.1           Amendment,
etc. This Warrant Certificate may only be amended and the obligations of the Company and the rights of the Warrantholder under
this Warrant Certificate may be amended, waived, discharged or terminated (either generally or in a particular instance, either
retroactively or prospectively and either for a specified period of time or indefinitely) by a written instrument signed by the
Company and the Warrantholder.


 


ARTICLE 8


MISCELLANEOUS


 


8.1           Time.
Time is of the essence of the terms of this Warrant Certificate.


 


8.2           Notice.
Any notice or other communication to be given in connection with this Warrant Certificate must be in writing and given by
(a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail (including PDF) or facsimile
during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s
next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested,
postage prepaid, or (d) one (1) business day after deposit with an internationally recognized overnight courier, freight
prepaid, specifying next business day delivery, with written verification of receipt, to the recipient at the address below
indicated:


 


If to the Company:


 


Stellar Biotechnologies, Inc.


332 E. Scott St.


Port Hueneme, CA 93041


Tel: (805) 488-2800 / Fax: (805) 488-2889


Attention: Chief Financial Officer


 


If to the Warrantholder:


 


To the address of such Holder set forth on the books
and records of the Company.


 


or such other address or to the attention of such other person as the recipient party shall have
specified by prior written notice to the sending party in accordance with the provisions of this paragraph 8.2.


 


8.3           Disposition
of Shares and Warrant.


 


 (a)          The
Holder hereby acknowledges that: (i) this Warrant and any Common Shares issuable upon exercise of the Warrant have not been
registered (A) under the 1933 Act on the ground that the issuance of this Warrant is exempt from registration under Section
4(a)(2) of the 1933 Act as not involving any public offering, or (B) under any applicable state securities law because the
issuance of this Warrant does not involve any public offering; and (ii) that the Company’s reliance on the registration
exemption under Section 4(a)(2) of the 1933 Act and under applicable state securities laws is predicated in part on the
representations hereby made to the Company by the Warrantholder. The Warrantholder represents and warrants that he, she or it
is acquiring this Warrant and will acquire Common Shares issuable upon exercise of the Warrant for investment for his, her or
its own account, with no present intention of dividing his, her or its participation with others or reselling or otherwise
distributing this Warrant or Common Shares issuable upon exercise of the Warrant.


 




    	 	A-9	 



     


    

 


 (b)          The
Warrantholder hereby agrees that he, she or it will not sell, transfer, pledge or otherwise dispose of (collectively, “Transfer
”) all or any part of this Warrant and/or Common Shares issuable upon exercise of the Warrant unless and until he,
she or it shall have first obtained an opinion, reasonably satisfactory to counsel for the Company, of counsel (competent in securities
matters, selected by the Warrantholder and reasonably satisfactory to the Company) to the effect that the proposed Transfer may
be made without registration under the 1933 Act and without registration or qualification under any United States state law.


 


 (c)          If,
at the time of issuance of Common Shares issuable upon exercise of the Warrant, no registration statement is in effect with respect
to such shares under applicable provisions of the 1933 Act and the Common Shares issuable upon exercise of the Warrant may not
be sold pursuant to Rule 144 of the 1933 Act, the Company may, at its election, require that any stock certificate evidencing Common
Shares issuable upon exercise of the Warrant shall bear the legend reading substantially as set forth in paragraph 3.6(a) above.
In addition, so long as the foregoing legend may remain on any stock certificate evidencing Common Shares issuable upon exercise
of the Warrant, the Company may maintain appropriate “stop transfer” orders with respect to such certificates and the
shares represented thereby on its books and records and with those to whom it may delegate registrar and transfer functions.


 


8.4           Transfer
of Warrants. Subject to applicable securities legislation (including, but not limited to, the 1933 Act) and the rules, policies,
notices and orders issued by applicable securities regulatory authorities, including the TSX Venture Exchange (or any other stock
exchange on which the Common Shares are listed), the Warrants evidenced hereby (or any portion thereof) may be assigned or transferred
by the holder by duly completing and executing the transfer form attached hereto as Schedule “C”. The rights and obligations
of the Company and Warrantholder shall be binding upon and enure to the benefit of their successors and permitted assigns.


 


8.5           Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record holder hereof from time to time. The Company may deem and treat the registered
holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the holder, and
for all other purposes, absent actual notice to the contrary.


 




    	 	A-10	 



     


    

 


SCHEDULE “B”


 


SUBSCRIPTION FORM


 


	TO:	Stellar Biotechnologies, Inc.
	 	332 E. Scott Street
	 	Port Hueneme, California 93041


 


The undersigned
Holder of the within Warrants hereby subscribes for common shares (the “Common Shares”) of STELLAR BIOTECHNOLOGIES,
INC. (the “Company”) pursuant to the within Warrants at US $1.35 per Common Share on the terms specified
in the said Warrants. This subscription is accompanied by a certified check, bank draft, wire transfer or a money order payable
to or to the order of the Company for the whole amount of the purchase price of the Common Shares.


 


In connection with this subscription: (check one):


 


		1.	 ̈ 	The
undersigned hereby certifies that (i) it is not a U.S. Person (as defined in Regulation S under the United States Securities Act
of 1933, as amended (the “U.S. Securities Act”), the definition of which includes, but is not limited to, any individual
resident in the United States, any partnership or corporation organized or incorporated under the laws of the United States, and
any estate or trust of which any administrator, executor or trustee is a U.S. Person), (ii) at the time of exercise it is not
within the United States and it did not execute and deliver this subscription form in the United States, and (iii) it is not exercising
any of the Warrants represented by this Warrant Certificate for or on behalf of any U.S. Person or person within the United States.



 


		2.	 ̈ 	The
undersigned hereby certifies that (i) it is an Accredited Investor (as defined in Rule 501(a) under the U.S. Securities Act) that
purchased the Warrants represented by this Warrant Certificate directly from the Company for its own account, (ii) it is exercising
the Warrants for its own account, and (iii) it remains an Accredited Investor on the date of exercise of the Warrants.



 


Note: The Common Shares will not
be registered or delivered to a U.S. address unless the undersigned has checked box 2 above and satisfied the applicable requirements
thereof. A legend will be placed on any Common Shares issued pursuant to box 2 above to the effect that the Common Shares may not
be transferred except pursuant to an exemption from registration under the U.S. Securities Act and all applicable state securities
laws.


 


The undersigned hereby directs that the Common Shares
be registered as follows:


 


	Name(s) in full	Address	Number of Common Shares
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 


 




    	 	B-1	 



     


    

 


DATED this                      day
of                                                           ,
20        .


 


	Name of Holder:	 
	 	 
	 	 
	 	 
	 	 
	Signature of Holder	 
	 	 
	 	 
	Mailing Address:	 
	 	 
	 	 


  


Instructions:


 





	1.	The signature to the subscription must be the signature of the person appearing on the face of the Warrant Certificate.


 


	2.	If there is more than one holder of the Warrants, all holders must sign.


 


	3.	In the case of persons signing by a trustee, executor, administrator, curator, guardian, attorney, officer of a corporation or any person acting in a fiduciary or representative capacity, the certificate must be accompanied by evidence of authority to sign satisfactory to the Company.


 


	4.	If the Warrant certificate and the form of subscription are being forwarded by mail, registered mail must be employed.





 












    	 	B-2	 



     


    

 


SCHEDULE “C”


TRANSFER FORM


 


	TO:	Stellar Biotechnologies, Inc.
	 	332 E. Scott Street
	 	Port Hueneme, California 93041


 


FOR
VALUE RECEIVED, the undersigned hereby sells, assigns and transfers
unto                                                                            (name)
(“Assignee”),
of                                                                  (address),                                                               Warrants
of STELLAR BIOTECHNOLOGIES, INC. (the “Company”) registered in the name of the undersigned on
the records of the Company represented by the within warrant certificate and irrevocably appoints                                                                 the
attorney of the undersigned to transfer the said securities on the books or register with full power of substitution.


 


The undersigned hereby
certifies that, by assignment hereof, the Warrant and the shares of stock to be issued upon exercise of the Warrant are being acquired
for investment and that the Assignee will not offer, sell or otherwise dispose of the Warrant or any shares of stock to be issued
upon exercise thereof except under circumstances which will not result in a violation of the United States Securities Act of 1933,
as amended, or any United States state securities laws. Further, the Assignee has acknowledged that upon exercise of this Warrant,
the Assignee shall, if requested by the Company, confirm in writing, in a form satisfactory to the Company, that the shares of
stock so purchased are being acquired for investment and not with a view toward distribution or resale.


 


DATED this               day
of                                         ,
20    _.


 


		 	
	 	 	 
	(Witness)	 	(Signature of Registered Warrant Holder)
	 	 	 
	 	 	 
	 	 	(Print name of Registered Warrant Holder)
	 	 	 
	Signature of transferor guaranteed by:	 	 
	 	*	 
	* Authorized Signature Number	 	 


 


NOTE: The signature of the Holder to this
assignment must correspond exactly with the name of the Holder as set forth on the face of this Warrant certificate in every particular,
without alteration or enlargement or any change whatsoever and the signature must be guaranteed by a Canadian chartered bank or
by a Canadian trust company or by a medallion signature guarantee from a member of a recognized Signature Medallion Guarantee Program.


 


Instructions:


  


	1.	Signature of transferor must be the signature of the person appearing on the face of the Warrant Certificate.
	2.	If there is more than one person appearing on the face of the Warrant Certificate, all must sign.
	3.	If the Transfer of Warrants is signed by a trustee, executor, administrator, curator, guardian, attorney, officer of a corporation or any person acting in a fiduciary or representative capacity, the certificate must be accompanied by evidence of authority to sign satisfactory to the Company.
	4.	If the Warrant certificate and the form of transfer are being forwarded by mail, registered mail must be employed.







 




    	 	C-1